1. Home
  2. PSQH vs TVRD Comparison

PSQH vs TVRD Comparison

Compare PSQH & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PSQ Holdings Inc.

PSQH

PSQ Holdings Inc.

HOLD

Current Price

$3.39

Market Cap

29.3M

ML Signal

HOLD

Logo Tvardi Therapeutics Inc.

TVRD

Tvardi Therapeutics Inc.

SELL

Current Price

$1.07

Market Cap

27.5M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PSQH
TVRD
Founded
2021
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.3M
27.5M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
PSQH
TVRD
Price
$3.39
$1.07
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
★ $9.25
AVG Volume (30 Days)
38.6K
★ 228.3K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
55.00
★ 79.01
EPS
N/A
★ N/A
Revenue
★ $5,685,987.00
$911,000.00
Revenue This Year
$81.45
N/A
Revenue Next Year
$35.13
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 1096.61
959.30
52 Week Low
$0.36
$0.93
52 Week High
$6.94
$6.43

Technical Indicators

Market Signals
Indicator
PSQH
TVRD
Relative Strength Index (RSI) 30.66 32.83
Support Level $0.51 $0.93
Resistance Level $5.73 $2.02
Average True Range (ATR) 0.35 0.08
MACD -0.12 0.01
Stochastic Oscillator 5.61 17.78

Price Performance

Historical Comparison
PSQH
TVRD

About PSQH PSQ Holdings Inc.

PSQ Holdings Inc operates the website and mobile application named as PublicSq. It is an app and website that connects freedom-loving Americans to high-quality businesses that share values, both online and in local communities. It has three reportable segments comprised of Marketplace; which includes a marketplace platform to access consumers that are drawn to patriotic values and the revenue is generated in the form of advertising and eCommerce transactions, and Brands segment in which through its wholly-owned brand, the company generates revenue from online sales of diapers and wipes and third financial technology which assists consumers, lenders, and retailers in offering point-of-sale financing products.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: